Answers are grounded in this paper and cite their sources.
In this study, an increase in the overall risk of second primary cancers after melanoma after the introduction of immune checkpoint inhibitors was observed. The pattern of SPCs has been altered in the era of systemic therapy. Close monitoring and screening for SPCs may be warranted in patients with metastatic melanoma.
No takes yet. Share an insight, caveat, or question.
Deng et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: